These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16703416)

  • 1. Impact of CCR5 Delta32/+ deletion on herpes zoster among HIV-1-infected homosexual men.
    Krol A; Lensen R; Veenstra J; Prins M; Schuitemaker H; Coutinho RA
    Eur J Epidemiol; 2006; 21(6):469-73. PubMed ID: 16703416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No evidence for an effect of the CCR5 delta32/+ and CCR2b 64I/+ mutations on human immunodeficiency virus (HIV)-1 disease progression among HIV-1-infected injecting drug users.
    Schinkel J; Langendam MW; Coutinho RA; Krol A; Brouwer M; Schuitemaker H
    J Infect Dis; 1999 Apr; 179(4):825-31. PubMed ID: 10068577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterozygosity for CCR5-Delta32 but not CCR2b-64I protects against certain intracellular pathogens.
    Ashton LJ; Stewart GJ; Biti R; Law M; Cooper DA; Kaldor JM
    HIV Med; 2002 Apr; 3(2):91-6. PubMed ID: 12010355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced prevalence of the CCR5 delta32 heterozygous genotype in human immunodeficiency virus-infected individuals with AIDS dementia complex.
    van Rij RP; Portegies P; Hallaby T; Lange JM; Visser J; de Roda Husman AM; van 't Wout AB; Schuitemaker H
    J Infect Dis; 1999 Sep; 180(3):854-7. PubMed ID: 10438379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infectious cellular load in human immunodeficiency virus type 1 (HIV-1)-infected individuals and susceptibility of peripheral blood mononuclear cells from their exposed partners to non-syncytium-inducing HIV-1 as major determinants for HIV-1 transmission in homosexual couples.
    Blaak H; van't Wout AB; Brouwer M; Cornelissen M; Kootstra NA; Albrecht-van Lent N; Keet RP; Goudsmit J; Coutinho RA; Schuitemaker H
    J Virol; 1998 Jan; 72(1):218-24. PubMed ID: 9420218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission.
    Hladik F; Liu H; Speelmon E; Livingston-Rosanoff D; Wilson S; Sakchalathorn P; Hwangbo Y; Greene B; Zhu T; McElrath MJ
    J Virol; 2005 Sep; 79(18):11677-84. PubMed ID: 16140745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of CCR5-Δ32 heterozygosity on HIV-1 susceptibility: a meta-analysis.
    Liu S; Kong C; Wu J; Ying H; Zhu H
    PLoS One; 2012; 7(4):e35020. PubMed ID: 22496885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCR5 genotype and HIV-1 infection in perinatally-exposed infants.
    Mas A; Español T; Heredia A; Pedraza MA; Hernandez M; Caragol I; Fernando M; Bertran JM; Alcami J; Soriano V
    J Infect; 1999 Jan; 38(1):9-11. PubMed ID: 10090498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
    Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
    HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between CCR5 genotype and the clinical course of HIV-1 infection.
    de Roda Husman AM; Koot M; Cornelissen M; Keet IP; Brouwer M; Broersen SM; Bakker M; Roos MT; Prins M; de Wolf F; Coutinho RA; Miedema F; Goudsmit J; Schuitemaker H
    Ann Intern Med; 1997 Nov; 127(10):882-90. PubMed ID: 9382366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection.
    Mulherin SA; O'Brien TR; Ioannidis JP; Goedert JJ; Buchbinder SP; Coutinho RA; Jamieson BD; Meyer L; Michael NL; Pantaleo G; Rizzardi GP; Schuitemaker H; Sheppard HW; Theodorou ID; Vlahov D; Rosenberg PS;
    AIDS; 2003 Feb; 17(3):377-87. PubMed ID: 12556692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variations in CC chemokine receptors and hypertension.
    Zhang M; Ardlie K; Wacholder S; Welch R; Chanock S; O'Brien TR
    Am J Hypertens; 2006 Jan; 19(1):67-72. PubMed ID: 16461193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection.
    Marmor M; Sheppard HW; Donnell D; Bozeman S; Celum C; Buchbinder S; Koblin B; Seage GR;
    J Acquir Immune Defic Syndr; 2001 Aug; 27(5):472-81. PubMed ID: 11511825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1-infected long-term slow progressors heterozygous for delta32-CCR5 show significantly lower plasma viral load than wild-type slow progressors.
    Walli R; Reinhart B; Luckow B; Lederer E; Loch O; Malo A; Wank R; Schlöndorff D; Goebel FD
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jul; 18(3):229-33. PubMed ID: 9665499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of CCR5-delta32 and CCR2-64I alleles on disease progression of perinatally HIV-1-infected children: an international meta-analysis.
    Ioannidis JP; Contopoulos-Ioannidis DG; Rosenberg PS; Goedert JJ; De Rossi A; Espanol T; Frenkel L; Mayaux MJ; Newell ML; Pahwa SG; Rousseau C; Scarlatti G; Sei S; Sen L; O'Brien TR;
    AIDS; 2003 Jul; 17(11):1631-8. PubMed ID: 12853745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of CCR5-Delta32 deletion in human immunodeficiency virus type 1 (HIV-1) in healthy blood donors, HIV-1-exposed seronegative and HIV-1-seropositive individuals of southern Brazilian population.
    Reiche EM; Ehara Watanabe MA; Bonametti AM; Morimoto HK; Akira Morimoto A; Wiechmann SL; Matsuo T; Carvalho De Oliveira J; Vissoci Reiche F
    Int J Mol Med; 2008 Nov; 22(5):669-75. PubMed ID: 18949389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased HIV type 1 transcription in CCR5-Δ32 heterozygotes during suppressive antiretroviral therapy.
    Wang C; Abdel-Mohsen M; Strain MC; Lada SM; Yukl S; Cockerham LR; Pilcher CD; Hecht FM; Sinclair E; Liegler T; Richman DD; Deeks SG; Pillai SK
    J Infect Dis; 2014 Dec; 210(11):1838-43. PubMed ID: 24935955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion.
    Sheppard HW; Celum C; Michael NL; O'Brien S; Dean M; Carrington M; Dondero D; Buchbinder SP
    J Acquir Immune Defic Syndr; 2002 Mar; 29(3):307-13. PubMed ID: 11873082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic expressions of CCR5-delta32/delta32 homozygosity.
    Nguyêñ GT; Carrington M; Beeler JA; Dean M; Aledort LM; Blatt PM; Cohen AR; DiMichele D; Eyster ME; Kessler CM; Konkle B; Leissinger C; Luban N; O'Brien SJ; Goedert JJ; O'Brien TR
    J Acquir Immune Defic Syndr; 1999 Sep; 22(1):75-82. PubMed ID: 10534150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of a 32 bp deletion in the gene for human immunodeficiency virus 1 co-receptor CCR5 in Slovak population.
    Takácová M; Nogová P; Hábeková M; Staneková D
    Acta Virol; 2008; 52(4):261-4. PubMed ID: 19143484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.